Clinical Trial Update: A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC [Phase 1, Phase 2]

View source ↗

Summary

Early-phase trial investigating cadonilimab in combination with regorafenib for advanced hepatocellular carcinoma (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cadonilimab
• Regorafenib (regorafenib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Advanced Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN